TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04868058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
Study: NCT00787605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Description: Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
Study: NCT04685343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing
Description: Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.
Study: NCT03168438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel with pembrolizumab
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study: NCT04868058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine : 0.4 ml/kg (ideal body weight!) of 5mg/ml (20 to 30 ml bolus dose (100-150 mg), maximum dose 200 mg ropivacaine
Study: NCT03168438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is available as an IV infusion
Study: NCT02049320

Intervention type: DRUG
Intervention: Remifentanil
Study: NCT04536025

Intervention type: OTHER
Intervention: Qualitative focus group interviews
Description: Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.

Intervention type: OTHER
Intervention: Qualitative focus group interviews
Description: Prosthetists and/or expert working group members will participate in qualitative focus group interviews up to 120 minutes in length.

Intervention type: OTHER
Intervention: Qualitative semi-structured interviews
Description: People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.

Intervention type: OTHER
Intervention: Qualitative semi-structured interviews
Description: People with lower limb amputation and/or expert working group members will participate in qualitative individual, semi-structured interviews approximately 60 minutes in length.
Study: NCT01598168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone intravenous
Study: NCT02572193

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM
Description: To determine the feasibility of same-day discharge following a POEM procedure
Study: NCT02271373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: increasing time spent outdoors
Description: The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravenous
Study: NCT03235843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AAIR pacing
Description: Rate adaptive pacing using a MV sensor.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DDI-pacing
Description: Rate adaptive pacing OFF
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron oral tablets
Study: NCT02325661

Intervention type: OTHER
Group type: OTHER
Intervention: cognitive interviewing
Description: For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation.
Study: NCT03191240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressins
Description: Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study: NCT00208299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: 0.4 mg, bolus intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine
Description: 0.14 mg/kg/min for 6 minutes, intravenous infusion
Study: NCT00410202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 100 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 100 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tablets, Oral, 300 mg, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 100 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 100 weeks
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron oral tablets
Study: NCT00410202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Tablets, Oral, 100mg, once daily, 100 weeks
Study: NCT00366834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron oral tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: casopitant placebo
Study: NCT00642473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Actavis
Description: Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Actavis
Description: Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-active Moisturizing Cream
Description: Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-active Moisturizing Cream
Description: Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
Study: NCT03219918

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRings II Distal Attachment
Description: Colonoscopy cap
Study: NCT04407481

Intervention type: DRUG
Intervention: Aminohippurate Sodium Inj 20%
Description: Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Intervention type: DRUG
Intervention: Iohexol Inj 300 milligrams per milliliter (MG/ML)
Description: Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Intervention type: RADIATION
Intervention: PET/CT Scan
Description: Imaging used to visualize the kidneys and quantify renal metabolic activity
Study: NCT01296438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
Study: NCT01178073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambrisentan
Description: ambrisentan (target dose: 10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ambrisentan
Description: ambrisentan (target dose: 10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil (target dose: 40mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil (target dose: 40mg)
Study: NCT02471976

Intervention type: OTHER
Group type: OTHER
Intervention: strategy promoting early consideration and collegiate vulnerability of patients
Description: One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
Study: NCT00484718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: oral, 100 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: oral, 20 mg bid
Study: NCT02193347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEPIDH1M vaccine
Description: PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus-Diphtheria Toxoid (Td)
Description: After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
Study: NCT00484718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral bid
Study: NCT02636374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: A fifteen minute recording of gentle music together with soft talking to guide relaxation.
Study: NCT04756869

Intervention type: OTHER
Intervention: COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology
Description: Health care workers are on-study for 30 days, in which they wear a smart watch and temperature patches up to daily. Subjects also may provide nasal and saliva samples up to daily during the study period, and they may opt-in to blood samples lasting up to 1 year after study completion. Through a smartphone app, participants complete surveys at baseline and at study completion, as well as daily mood surveys and symptom-reporting surveys. Finally, exit interviews occur at the end of the study period, and follow-up interviews may occur at specified timepoints up to 1 year after study completion.
Study: NCT01461278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent supra
Description: Cataract surgery and implantation of one iStent supra

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery alone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Cataract surgery alone
Study: NCT03356054

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: R-DHAP
Description: 3 cycles q 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: 3 cycles q 3 weeks added to R-DHAP
Study: NCT00861536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG Fresenius
Description: Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobuline Genzyme
Description: Day 0-3: 1.5 mg/kg bw/d
Study: NCT01917929

Intervention type: DEVICE
Group type: OTHER
Intervention: Secur-Fit Advanced Hip Stem
Description: Straight femoral stem intended for cementless, press-fit application.
Study: NCT01302379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle intervention
Description: Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard printed dietary guidelines
Description: Set of standard health education materials provided to participants at single time point (immediately after randomization)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard printed dietary guidelines
Description: Set of standard health education materials provided to participants at single time point (immediately after randomization)
Study: NCT03589781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mikei Red Reishi Essence EX
Description: Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
Study: NCT02826850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saphenous Nerve
Description: Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
Study: NCT03862521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: Low carbohydrate diet
Study: NCT02826850

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Genicular nerves
Description: Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
Study: NCT03986151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
Study: NCT03862521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet
Description: Very low carbohydrate diet
Study: NCT04530344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study: NCT00832780

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
Study: NCT02193347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
Study: NCT03199534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 50u
Description: Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 100u
Description: Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A 150u
Description: Subject will receive injection of 150u Botulinum toxin A while anesthetized.
Study: NCT04069169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
Study: NCT00952562

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Empty capsules, 3 capsules per day for 16 weeks
Study: NCT01258699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocacid HR Tab 600mg
Description: 600mg for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BK-C-0701 320mg
Description: 320mg for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BK-C-0701 480mg
Description: 480mg for 1 day
Study: NCT04019704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: Oral AXS-05 tablets, taken daily for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
Study: NCT01348906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intermittent normoxia
Description: 3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
Study: NCT02065011

Intervention type: DRUG
Group type: OTHER
Intervention: Blood draw for the laboratory assessment
Study: NCT03109067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized meal
Description: Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
Study: NCT04427345

Intervention type: OTHER
Intervention: Predictive factors for clinical response in patients with COVID-19.
Description: Identify the risk factors for intra-hospital mortality in patients hospitalized in the COVID + hospital wards of the San Gerardo hospital and build a prognostic score through which it is possible to define a stratification that immediately guides the therapeutic choices and the intensity of care .